BRIEF—Vertex wins EU nod for Symkevi combo in cystic fibrosis

London’s Vertex Pharmaceuticals has won European approval for Symkevi (tezacaftor/ivacaftor) in combination with Kalydeco (ivacaftor) to treat certain people with cystic fibrosis (CF).

The combination was approved in the USA in February 2018 and in Canada in June 2018. It is marketed as Symdeko in these countries.

Chief medical officer Reshma Kewalramani said: “Today marks an important milestone for many CF patients in Europe, including those who so far have had no available option to treat the CFTR protein defect responsible for their disease.”

“With today’s Marketing Authorization, we are rapidly moving towards treating 90 percent of CF patients.”